Monitor upcoming BLA submission in Q4 2026 and FDA review timeline. The partnership reduces execution risk for launch but adds no near-term revenue. Watch for potential partnership expansions or licensing deals.
Price Chart
Executive Summary
Candel Therapeutics entered into a commercialization agreement with EVERSANA to support the potential U.S. launch of aglatimagene (CAN-2409) for intermediate- to high-risk localized prostate cancer, pending BLA submission planned for Q4 2026. The partner-led model preserves financial flexibility but provides no guaranteed revenue. This is a routine pre-commercialization step with no disclosed financial terms.
Key Facts
- Candel entered a product commercialization agreement with EVERSANA for potential U.S. launch of CAN-2409.
- BLA submission for CAN-2409 in localized prostate cancer is planned for Q4 2026.
- EVERSANA will provide data/analytics, medical affairs, market access, and field operations.
- No financial terms or upfront payments disclosed.
- Candel remains a clinical-stage biopharmaceutical company with no approved products.
Financial Impact
No dollar amounts disclosed; financial impact contingent on future regulatory approval and commercial success.
Risk Factors
- CAN-2409 may not receive FDA approval; BLA submission is planned but not guaranteed.
- Commercial launch requires regulatory approval and market acceptance; competition from existing prostate cancer therapies.
- Candel has no approved products and relies on financing to support operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283732 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $10.16 | awaiting T+60 | — | $7.79 (−23.33%) |
Sep 30, 2026 26d ago | Press Release | $10.44 | awaiting T+60 | — | $7.79 (−25.38%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $7.79 (−35.94%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 3, 2026 12w ago | Press Release | $10.07 | awaiting T+60 | — | $7.79 (−22.64%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers